1) quantitative HBeAg
HBeAg定量
1.
There were some relevences between HBV-DNA loading and quantitative HBeAg,yet the kappa coefficient was only 0.
49;HBV-DNA定量和HBeAg定量之间相关系数(r)为0。
2) HBeAg positive
HBeAg阳性
1.
Comparison of differential diagnosis and correlated indexes in patients with chronic hepatitis b with HBeAg positive or negative
HBeAg阳性与阴性慢性乙型肝炎患者中医辨证及其相关指标的比较
2.
Objective:To study the relationship of the time sequence between the serum HBV DNA relapse and YMDD mutation in the Lamivudine treating patients with HBeAg positive chronic hepatitis B.
目的:研究拉米夫定治疗HBeAg阳性慢性乙型肝炎(CHB),血清HBVDNA反跳发生时间与YMDD变异的关系。
3.
[Objective]To observe the efficacy of Adefovir dipivoxil(ADV)monotherapy for HBeAg positive patients with chronic hepatitis B,evaluate the influence of baseline ALT and HBV DNA level on biochemical and virological response of Adefovir dipivoxil monotherapy,evaluate relationship between CD4~+/CD8~+ ratio change during treatment to response of Adefovir dipivoxil monotherapy.
[研究目的]:观察阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者的疗效,观察不同基线ALT、HBV DNA水平的患者治疗后血清生化学与病毒学应答情况,观察治疗24周后的CD4~+/CD8~+的变化与治疗应答的关系,并初步探讨临床实用的疗效预测指标。
3) HBeAg-negative
HBeAg阴性
1.
Research Progress of HBeAg-negative Chronic Hepatitis B
HBeAg阴性慢性乙型肝炎研究进展
2.
To investigate the effect ofα-interferon (INF-α)therapy for HBeAg-negative chronic hepatitis B (CHB).
了解干扰素治疗HBeAg阴性慢性乙型肝炎的疗效。
3.
Objective To probe into the clinical characteristic of the HBeAg-negative chronical hepatitis-B(e-CHB for short)and its relationships with the G1896A mutation in the precore and with the A1762T/G1764A twin-mutation in the basal core promoter(BCP for short).
目的探讨HBeAg阴性慢性乙型肝炎(以下简称e-CHB)的临床特点及与前C区G1896A变异及基本核心启动子(BCP)区A1762T/G1764A双变异的关系。
4) HBeAg negative
HBeAg阴性
1.
The preliminary observation of adefovir treatment for 46 patients with HBeAg negative chronic hepatitis B;
阿德福韦治疗HBeAg阴性慢性乙型肝炎患者的初步观察
2.
Study on relationgship between viral dynamics change and curative effect in patients with HBeAg negative chronic hepatitis B treated with adefovir
阿德福韦治疗HBeAg阴性慢性乙型肝炎患者病毒动力学变化与疗效关系的研究
3.
Study on clinical and pathological characteristic in HBeAg negative chronic hepatitis B patients with nonalcoholic fatty liver disease
HBeAg阴性慢性乙型肝炎并非酒精性脂肪性肝病56例临床及病理特征
5) negative HBeAg
HBeAg阴性
1.
The long-term clinical efficacy of lamivudine in treatment of chronic hepatitis B with negative HBeAg;
拉米夫定治疗HBeAg阴性的慢性乙型肝炎的长期疗效
6) HBeAg-positive
HBeAg阳性
1.
The Clinical Efficacy of the Adefovir Dipivoxil in the Treatment of 36 Chronic Hepatitis B Patients with HBeAg-positive
阿德福韦酯(贺维力)治疗HBeAg阳性慢性乙型肝炎36例临床疗效观察
补充资料：[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式：C16H16ClN3O3S
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条